I. COMMENCED TRADING IN NOVEMBER

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

INITIAL OFFERINGS

There were no initial public offerings in November.

Total: $0M

Number of IPOs in November: 0

Average value of November IPOs: $0M

Number of IPOs for 2001: 7

Total raised in IPOs in 2001: $207.05M

Average value of IPOs in 2001: $29.58M

FOLLOW-ON OFFERINGS

Company (Symbol)#

Date Filed

Date Comm.

Shares/Units (M)

Price

Shares Out (M)

Lead, Other Underwriters

Gross (M)

Net (M)

ICOS Corp. (ICOS)1

6/26

11/8

5.5

$57

59

CS First Boston (co-lead)
Merrill Lynch & Co. (co-lead)
SG Cowen Securities Corp.
Banc of America Securities LLC
Robertson Stephens Inc.

$313.5

$297.3

ILEX Oncology Inc. (ILXO)2

10/29

11/15

5.75S

$24

31.5

CIBC World Markets (co-lead)
UBS Warburg LLC (co-lead)
U.S. Bancorp Piper Jaffray

$138

$129.1

Labopharm Inc. (Canada; TSE:DDS)3

10/29

11/8

5.2S

C$6.75

N/A

Research Capital Corp.
CIBC World Markets Corp.
National Bank Financial Inc.
TD Securities Inc.

C$35.1
(US$22.2)

N/A

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange; TSE = Toronto Stock Exchange

N/A = Not available, applicable or reported.

1 ICOS' underwriters have an option for another 815,789 shares to cover overallotments.

2 ILEX's offering includes the full exercise of the underwriters' overallotment option for 750,000 shares.

3 Labopharm's offering includes 1.2M shares that were issued as a result of an option to the underwriters of the offering.

Total: $473.7M

Number of follow-on offerings in November: 3

Average value of November follow-ons: $157.9

Number of follow-on offerings in 2001: 34

Total raised in follow-ons in 2001: $2,952.41M

Average value of follow-ons in 2001: $86.8M

II. FILED AND PENDING

Company (Symbol/Proposed Symbol)#*

Date Filed

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

AgraQuest Inc. (AGRQ)1

8/3

N/A

N/A

N/A

Merrill Lynch & Co.
Stephens Inc.
First Union Securities Inc.

$75

Antisense Therapeutics Ltd. (Australia)2

11/21**

N/A

N/A

N/A

N/A

A$13
(US$6.73)

APBiotech (APBI; unit of Nycomed Amersham plc)3

10/3/00

18.2S

$15-17

208.6

Morgan Stanley Dean Witter (co-lead)
Goldman, Sachs & Co. (co-lead)
Chase H&Q
Salomon Smith Barney

$291.2

CombiMatrix Corp. (CLMX)4

11/22/00

N/A

N/A

N/A

Salomon Smith Barney (co-lead)
JP Morgan & Co. (co-lead)

$100

diaDexus Inc. (DDXS)5

11/20

7S

$12-14

31.1

Lehman Brothers Inc.
CIBC World Markets Corp.
Robertson Stephens Inc.
Fidelity Capital Markets

$91

NeoGenesis Pharmaceuticals Inc. (NGPI)6

11/19

N/A

N/A

N/A

JP Morgan & Co.
Bear, Stearns & Co. Inc.
SG Cowen Securities

$115

Northwest Biotherapeutics Inc. (NWBT)7

8/13

3.5S

$8-$10

16.5

C.E. Unterberg, Towbin
Fahnestock & Co. Inc.
Roth Capital Partners LLC

$31.5

Ribapharm Inc. (RIBA)8

5/15

18S

$13-15

N/A

UBS Warburg LLC
CIBC World Markets Corp.

$252

Xcyte Therapies Inc. (XCYT)9

12/22

N/A

N/A

N/A

SG Cowen Securities Corp. (co-lead)
U.S. Bancorp Piper Jaffray (co-lead)
Dain Rauscher Inc.
First Security Van Kasper Inc.

$86.2

ZymoGenetics Inc. (ZGEN)10

9/10

N/A

N/A

N/A

Lehman Brothers Inc. (co-lead)
Merrill Lynch & Co. (co-lead)
Bear, Stearns & Co. Inc.
Pacific Growth Equities Inc.

$180

FOLLOW-ON OFFERINGS

Antigenics Inc. (AGEN)11

11/27

N/A

N/A

N/A

N/A

$100

BioMarin Pharmaceutical Inc. (BMRN)12

11/12

6S

$12.12

42

UBS Warburg LLC
CIBC World Markets Corp.
U.S. Bancorp Piper Jaffray

$72.7

Cell Pathways Inc. (CLPA)13

2/7

N/A

N/A

N/A

N/A

$25

Cerus Corp. (CERS)14

8/13

N/A

N/A

15.7

N/A

$300

CollaGenex Pharmaceuticals Inc. (CGPI)15

10/26

0.965S

$8.01

N/A

N/A

$7.7

Cytogen Corp. (CYTO)16

10/26

10S

$2.50

78.9

N/A

$25

Exelixis Inc. (EXEL)17

7/30

N/A

N/A

49.2

N/A

$150

Genaissance Pharmaceuticals Inc. (GNSC)18

10/18

N/A

N/A

22.8

N/A

$35

Genaera Corp. (GENR)19

11/21

N/A

N/A

N/A

N/A

$50

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)20

11/26

6.145S

C$7
(US$4.40)

N/A

BMO Nesbitt Burns Inc.
Raymond James Ltd.
RBC Capital Markets Inc.
Yorkton Securities Inc.
Dlouhy Merchant Group Inc.

C$43
(US$27)

InSite Vision Inc. (AMEX:ISV)21

2/2

N/A

N/A

N/A

Ladenburg Thalmann & Co.
(placement agent)

$40

Matrix Pharmaceuticals Inc. (MATX)22

5/25

N/A

N/A

26

N/A

$30

Medicure Inc. (Canada; CDNX: MPH)23

11/14

N/A

N/A

N/A

N/A

C$10
(US$6.3)

Microcide Pharmaceuticals Inc. (MCDE)24

2/12

N/A

N/A

N/A

N/A

$35

Myriad Genetics Inc. (MYGN)25

11/9

N/A

N/A

N/A

N/A

$250

NeoTherapeutics Inc. (NEOT)26

1/3

N/A

N/A

21.9

N/A

$50

Neurocrine Biosciences Inc. (NBIX)27

11/13

3.25S

$44.97

29.5

Deutsche Banc Alex. Brown (co-lead)
Credit Suisse First Boston (co-lead)
CIBC World Markets Corp.
Lehman Brothers Inc.
UBS Warburg LLC

$146.2

SciClone Pharmaceuticals Inc. (SCLN)28

11/6

N/A

N/A

N/A

N/A

$20

Theratechnologies Inc. (Canada; TSE:TH)29

11/27

2.5S

C$10.25

N/A

Yorkton Securities Inc.

C$26
(US$16)

Tularik Inc. (TLRK)30

8/14

N/A

N/A

49.2

N/A

$250

Valentis Inc. (VLTS)31

9/27

N/A

N/A

29.9

N/A

$45

Vysis Inc. (VYSI)32

8/8

1S

$25.96

11.2

UBS Warburg LLC
First Union Securities Inc.
Pacific Growth Equities Inc.

$26

III. WITHDRAWN AND POSTPONED

Company (Symbol/Proposed Symbol)*

Date Filed/Date Pulled

Shares/Units (M)

Price Range

Shares Out (M)

Lead, Other Underwriters

Value (M)

INITIAL OFFERINGS

BioNumerik Pharmaceuticals Inc. (BNPI)33

3/2
11/20

N/A

N/A

N/A

Morgan Stanley Dean Witter
UBS Warburg LLC
SG Cowen Securities Corp.

$50

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

* Stock symbols for companies seeking to complete IPOs are proposed.

N/A = Not available, applicable or reported.

AMEX = American Stock Exchange; CDNX = Canadian Stock Exchange; TSE = Toronto Stock Exchange

1 AgraQuest filed a registration statement with the SEC to raise $75M in an IPO.

2 Antisense, a spin-off of Circadian Technologies Ltd., is seeking to raise US$6.73M in an IPO conducted on Australia's stock exchange.

3 APBiotech's IPO value, $291.2M, is based on the sale of 18.2M shares at $16 each, the midpoint of the expected price range.

4 CombiMatrix did not disclose any further details.

5 diaDexus' IPO value, $91M, is based on the sale of 7M shares at $13, the midpoint of the expected price range. The underwriters have an overallotment option for 1.05M shares.

6 NeoGenesis filed for an IPO to raise $115M.

7 Northwest filed in August for an IPO expected to raise $48.3M. It amended the filing in October to raise $35M, and amended it in November to raise about $31.5M. The underwriter has an overallotment option for an additional 525,000 shares.

8 Ribapharm's IPO originally was proposed in June 2000. The company amended its prospectus on May 15. The value, $252M, is based on the offering of 18M shares at $14 each, the midpoint of the expected price range. The underwriters have an overallotment option for 2.7M shares.

9 Xcyte did not disclose any further details.

10 ZymoGenetics filed to raise $180M in an IPO.

11 Antigenics filed a shelf registration covering the issuance of various types of securities, including secured and unsecured debt securities, preferred stock, depository shares and common stock.

12 BioMarin's underwriters have an overallotment option for up to 900,000 shares.

13 Cell Pathways filed a shelf registration for the sale of $25M in common stock.

14 Cerus filed to sell up to $300M of common stock and debt in a shelf offering.

15 The value of CollaGenex's proposed offering, $7.7M, is based on the Oct. 26 closing stock price of $8.01.

16 Cytogen filed to offer 10M shares at about $2.50 each in a shelf registration.

17 Exelixis filed a shelf registration to sell up to $150M in common stock.

18 Genaissance filed a shelf registration to offer and sell common stock, preferred stock, debt or warrants, up to a value of $35M.

19 Genaera filed a universal shelf registration statement for the sale of up to $50M in common stock, preferred stock or warrants to purchase common stock or preferred stock.

20 Inex intends to raise about US$27M in the offering, which is expected to close on or about Dec. 13.

21 InSite filed a shelf registration in February to sell $40M in stock.

22 Matrix filed a shelf registration covering up to $30M in securities.

23 Medicure plans to offer units, each consisting of one common share and one common share purchase warrant exercisable for a period of 24 months. The price will be determined in the context of the market.

24 Microcide filed a shelf registration for the sale of up to $35M in securities. (Microcide is now Essential Therapeutics Inc., formed through its merger with The Althexis Company Inc.)

25 Myriad filed a shelf registration statement for the sale of up to $250M of various types of securities.

26 NeoTherapeutics filed a shelf registration covering the sale of debt securities, common stock, preferred stock, depository shares or warrants up to $50M. In May, the company raised $6M in a private placement. In August, the company privately placed 600,000 shares, raising $2.01M. In November, it placed 950,000 shares, raising $3.8M.

27 Neurocrine filed to sell 3.25M shares. The offering's value, $146.2M, is based on the Nov. 27 closing stock price of $44.97. The underwriters have an overallotment option for 487,500 shares.

28 SciClone filed to sell up to $20M in common and preferred stock, debt securities and warrants from time to time through a shelf offering.

29 Theratechnologies' underwriters have an option to purchase an additional 382,000 common shares. The deal is expected to close Dec. 13.

30 Tularik filed to sell up to $250M in common stock and debt securities.

31 Valentis filed to sell up to $45M worth of equity warrants, preferred and common stock through a shelf registration statement.

32 Vysis registered to sell 4M shares, 3M of which will be sold by shareholder BP plc. The value of the offering, $26M, is based on the closing stock price of $25.96 on Aug. 7. The underwriters have an overallotment option for 600,000 shares. (Vysis is now being purchased by Abbott Laboratories.)

33 BioNumerik withdrew its IPO, citing market conditions.